Advertisement
GILD vs MRK
Which Stock Would AI Choose? Gilead Sciences (GILD) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- GILD and MRK both operate in the pharmaceuticals sector, with GILD emphasizing HIV treatments and oncology expansion, while MRK relies heavily on its blockbuster Keytruda immunotherapy.
- Recent market activity shows similar year-to-date gains around 7-8%, but MRK has delivered stronger one-year returns of approximately 40% compared to GILD's 31%.
- GILD trades at a lower price-to-earnings (P/E) ratio of about 19x trailing twelve months (TTM), suggesting relative value versus MRK's higher 32x P/E amid growth expectations.
- MRK offers a slightly higher dividend yield at 3.03% compared to GILD's 2.49%, appealing to income-focused investors.
- Recent catalysts include GILD's acquisitions bolstering its oncology pipeline and MRK's strong quarterly earnings with upgraded guidance.
- Analyst targets suggest upside for both, with GILD at around $158 and MRK at $130 from current levels.
Introduction
Gilead Sciences (GILD) and Merck & Co. (MRK) represent two pillars of the pharmaceutical industry, both navigating patent landscapes and pipeline innovations amid evolving market dynamics. This stock comparison analyzes their recent performance, business drivers, and relative positioning, aiding traders seeking short-term momentum and long-term investors prioritizing stability and dividends. With healthcare stocks sensitive to clinical trial outcomes and regulatory approvals, understanding these contrasts helps in portfolio diversification and informed decision-making in the current environment.
GILD Overview and Recent Performance
Gilead Sciences (GILD), a biopharmaceutical leader, focuses on HIV/AIDS therapies like Biktarvy, oncology treatments such as Trodelvy, and emerging areas including CAR-T cell therapies. In recent weeks, GILD shares have shown resilience, trading around $132 with year-to-date gains of nearly 8% and one-year returns exceeding 30%. Positive sentiment stems from strategic acquisitions totaling over $16 billion to bolster its oncology and immunology pipelines, alongside promising Phase 3 data for Trodelvy outperforming competitors in certain trials. Market cap stands at approximately $163 billion, with a trailing P/E (price-to-earnings) ratio of 19.4 indicating value relative to peers. Dividend yield of 2.5% supports steady income, though growth beyond virology remains a key watchpoint amid broader market volatility.
MRK Overview and Recent Performance
Merck & Co. (MRK), a global healthcare giant, derives significant revenue from Keytruda in oncology, alongside vaccines like Gardasil and new HIV regimens. Shares recently closed near $112, reflecting year-to-date appreciation of about 7% and robust one-year gains of 40%, outpacing GILD. Recent quarterly results exceeded expectations with $16.3 billion in revenue, prompting an upgraded full-year outlook driven by oncology strength and product launches. With a $277 billion market cap and trailing P/E of 31.5, MRK commands a premium for its growth profile. A 3% dividend yield enhances appeal, while FDA approvals for novel therapies signal continued pipeline momentum despite patent expiration risks.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 AI trading bots from over 350 available, selecting only those best suited to prevailing market conditions across thousands of tickers. These bots employ diverse strategies like trend trading, swing trading, and volatility plays on timeframes from 5 minutes to 49 days, with impressive stats: annualized returns ranging 24% to 163%, win rates of 51% to 88%, and profit factors up to 11.7. None currently focus on GILD or MRK, but they target high-momentum sectors including semis, AI infrastructure, and industrials. Explore these bots to automate trading with data-driven signals tailored to your style.
Head-to-Head Comparison
GILD and MRK share sector exposure in drug manufacturing but diverge in business models: GILD transitions from HIV dominance to oncology diversification via acquisitions, while MRK leverages Keytruda's market leadership with broader vaccines and animal health. Growth drivers favor MRK's recent earnings momentum and new approvals, contrasting GILD's value-oriented pipeline buildout. Recent momentum tilts to MRK with superior one-year returns, though GILD exhibits lower volatility and cheaper valuation. Risk factors include patent cliffs for both flagships, but MRK's larger scale offers resilience. Market sentiment leans positive for MRK's catalysts versus GILD's steady HIV base, highlighting trade-offs in growth versus stability.
Tickeron AI Verdict
Tickeron's AI currently favors MRK due to consistent trend strength, recent earnings beats, upgraded guidance, and superior relative performance positioning. Observable factors like oncology revenue growth and higher analyst conviction suggest higher probability of near-term outperformance, though GILD's value metrics provide a compelling counterbalance for risk-averse strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Buy and MRK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GILD’s FA Score shows that 3 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).
- GILD’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GILD’s TA Score shows that 5 TA indicator(s) are bullish while MRK’s TA Score has 3 bullish TA indicator(s).
- GILD’s TA Score: 5 bullish, 3 bearish.
- MRK’s TA Score: 3 bullish, 6 bearish.
Price Growth
GILD (@Pharmaceuticals: Major) experienced а +0.63% price change this week, while MRK (@Pharmaceuticals: Major) price change was -1.62% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.00%. For the same industry, the average monthly price growth was -0.65%, and the average quarterly price growth was +2.68%.
Reported Earning Dates
GILD is expected to report earnings on Jul 30, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.00% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GILD | MRK | GILD / MRK | |
| Capitalization | 166B | 275B | 60% |
| EBITDA | 14.5B | 19.4B | 75% |
| Gain YTD | 9.401 | 6.502 | 145% |
| P/E Ratio | 18.17 | 31.35 | 58% |
| Revenue | 29.7B | 65.8B | 45% |
| Total Cash | 7.64B | 5.7B | 134% |
| Total Debt | 22.2B | 49.1B | 45% |
GILD | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 13 | 52 | |
SMR RATING 1..100 | 22 | 47 | |
PRICE GROWTH RATING 1..100 | 56 | 50 | |
P/E GROWTH RATING 1..100 | 68 | 5 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (19) in the Biotechnology industry is in the same range as MRK (22) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to MRK’s over the last 12 months.
GILD's Profit vs Risk Rating (13) in the Biotechnology industry is somewhat better than the same rating for MRK (52) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than MRK’s over the last 12 months.
GILD's SMR Rating (22) in the Biotechnology industry is in the same range as MRK (47) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (50) in the Pharmaceuticals Major industry is in the same range as GILD (56) in the Biotechnology industry. This means that MRK’s stock grew similarly to GILD’s over the last 12 months.
MRK's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for GILD (68) in the Biotechnology industry. This means that MRK’s stock grew somewhat faster than GILD’s over the last 12 months.
| GILD | MRK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 52% | N/A |
| Stochastic ODDS (%) | 2 days ago 43% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 70% | 2 days ago 57% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 48% |
| TrendMonth ODDS (%) | 2 days ago 48% | 2 days ago 42% |
| Advances ODDS (%) | 7 days ago 61% | 7 days ago 53% |
| Declines ODDS (%) | 5 days ago 46% | 2 days ago 50% |
| BollingerBands ODDS (%) | 2 days ago 47% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 52% | 2 days ago 45% |
Advertisement